“SGI (NYSE: SGI) today announced the installation of a
Linux-OS-based solution for bioinformatics computing at
Bristol-Myers Squibb Company (NYSE: BMY), one of the world’s
leading diversified global health and personal care companies.
Working together with Incyte Genomics, Inc. (Nasdaq: INCY), SGI
Global Services delivered a bioinformatics solution that allows
Bristol-Myers Squibb to increase its raw computing power, deploy
new scientific applications for Linux environments and extend
technology investments by increasing productivity and reducing
hardware and administrative costs.”
“The solution deployed at Bristol-Myers Squibb reinforces SGI’s
long-term commitment to life sciences, Linux and the open source
community and demonstrates SGI’s expertise in developing and
deploying customized solutions for its customers. Bristol-Myers
Squibb will use a Linux cluster from Incyte to conduct research for
genomics projects, including DNA and protein sequence analysis,
transcriptional profiling, and proteomics, one of the fastest
growing segments of bioinformatics research.”
“The SGI Origin family server sitting with a cluster of Linux
machines behind it is the ideal environment for the type of
computational research we conduct,” said Nathan Siemers, group
leader of bioinformatics at Bristol-Myers Squibb. “Some things we
do take quite a bit of horsepower. The hybrid combination of Linux
and SGI IRIX gives us the flexibility to do what we want, in a
manner transparent to our researchers.”